| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
123,000,000 |
| Market
Cap: |
956.94(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$6.78 - $11.94 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 6.9 |
| Insider 6 Months : 6.9 |
| Insider 3/6 Months : 13.9 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Outlook Therapeutics is a late clinical-stage biopharmaceutical company focused on developing and launching ophthalmic formulation of bevacizumab approved by the U.S. Food and Drug Administration for use in retinal indications. ONS-5010 (LYTENAVA (bevacizumab-vikg)), Co.'s sole product candidate in active clinical development, is an investigational ophthalmic formulation of bevacizumab, which it is developing to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (AMD) and other retinal diseases. Co.'s clinical program for ONS-5010 in wet AMD involves three clinical trials, which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
778,652 |
778,652 |
778,652 |
1,071,920 |
| Total Buy Value |
$48,485 |
$48,485 |
$48,485 |
$414,759 |
| Total People Bought |
3 |
3 |
3 |
7 |
| Total Buy Transactions |
3 |
3 |
3 |
13 |
| Total Shares Sold |
0 |
0 |
0 |
951,155 |
| Total Sell Value |
$0 |
$0 |
$0 |
$1,090,296 |
| Total People Sold |
0 |
0 |
0 |
2 |
| Total Sell Transactions |
0 |
0 |
0 |
5 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mcandrew Stephen J |
SVP Bus. Strat. & Dev. |
• – – |
2017-12-22 |
4 |
S |
$1.13 |
$17,747 |
D/D |
(15,705) |
50,899 |
|
- |
|
| Kenyon Lawrence A |
CFO and Secretary |
• – – |
2017-12-22 |
4 |
S |
$1.13 |
$29,566 |
D/D |
(26,165) |
67,313 |
|
- |
|
| Mohan Pankaj |
President & CEO |
• • • |
2017-12-19 |
4 |
S |
$1.14 |
$95,313 |
D/D |
(83,608) |
7,171,230 |
|
- |
|
| Yamashita Elizabeth A. |
VP, Regulatory Affairs |
• – – |
2017-12-19 |
4 |
S |
$1.14 |
$7,012 |
D/D |
(6,151) |
80,818 |
|
- |
|
| Mohan Pankaj |
President & CEO |
• • • |
2017-12-18 |
4 |
S |
$1.17 |
$24,012 |
D/D |
(20,523) |
7,254,838 |
|
- |
|
| Yamashita Elizabeth A. |
VP, Regulatory Affairs |
• – – |
2017-12-18 |
4 |
S |
$1.17 |
$1,766 |
D/D |
(1,509) |
86,969 |
|
- |
|
| Hilzinger Kurt J |
Director |
– • – |
2017-01-23 |
4 |
OE |
$0.01 |
$120 |
D/D |
12,036 |
30,554 |
|
- |
|
| Kenyon Lawrence A |
CFO and Secretary |
• – – |
2016-12-21 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
93,478 |
|
- |
|
| Mcandrew Stephen J |
SVP Bus. Strat. & Dev. |
• – – |
2016-12-21 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
66,604 |
|
- |
|
| Gangloff Scott A. |
SVP, Development & Mfrg |
• – – |
2016-12-21 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
118,573 |
|
- |
|
| Yamashita Elizabeth A. |
VP, Regulatory Affairs |
• – – |
2016-12-21 |
4 |
A |
$0.00 |
$0 |
D/D |
45,000 |
88,478 |
|
- |
|
| Bahrt Kenneth |
Chief Medical Officer |
• – – |
2016-12-21 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
80,985 |
|
- |
|
| Bao Kogan |
VP, Analytical Sciences |
• – – |
2016-12-21 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
71,739 |
|
- |
|
| Hilzinger Kurt J |
Director |
– • – |
2016-11-30 |
4 |
A |
$0.00 |
$0 |
D/D |
6,885 |
18,518 |
|
- |
|
| Hilzinger Kurt J |
Director |
– • – |
2016-11-28 |
4 |
A |
$0.00 |
$0 |
D/D |
11,633 |
11,633 |
|
- |
|
| Smith Hoke Robin |
Director |
– • – |
2016-11-28 |
4 |
A |
$0.00 |
$0 |
D/D |
1,939 |
1,939 |
|
- |
|
| Canute Scott A |
Director |
– • – |
2016-11-28 |
4 |
A |
$0.00 |
$0 |
D/D |
57,408 |
246,342 |
|
- |
|
| Griffith Donald J. |
|
– • – |
2016-11-23 |
4 |
S |
$3.75 |
$4 |
D/D |
(1) |
144,926 |
|
- |
|
| Gangloff Scott A. |
SVP, Development & Mfrg |
• – – |
2016-11-11 |
4 |
S |
$3.75 |
$140,134 |
D/D |
(37,369) |
78,573 |
|
- |
|
| Mcandrew Stephen J |
SVP Bus. Strat. & Dev. |
• – – |
2016-11-11 |
4 |
S |
$3.75 |
$80,126 |
D/D |
(21,367) |
36,604 |
|
- |
|
| Gangloff Scott A. |
SVP, Development & Mfrg |
• – – |
2016-11-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
115,942 |
115,942 |
|
- |
|
| Gangloff Scott A. |
SVP, Development & Mfrg |
• – – |
2016-11-09 |
4 |
A |
$0.00 |
$0 |
D/D |
115,942 |
0 |
|
- |
|
| Griffith Donald J. |
|
– • – |
2016-11-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
144,927 |
144,927 |
|
- |
|
| Griffith Donald J. |
|
– • – |
2016-11-09 |
4 |
A |
$0.00 |
$0 |
D/D |
144,927 |
0 |
|
- |
|
| Mcandrew Stephen J |
SVP Bus. Strat. & Dev. |
• – – |
2016-11-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
57,971 |
57,971 |
|
- |
|
151 Records found
|
|
Page 5 of 7 |
|
|
0.45 (6.14%) 
